Cyber Sale, Massive Discounts Await
I understand that I will be charged every 3 months for my cycle subscription.
Observed performance metrics in laboratory models
Observed performance metrics in laboratory models
Research summary on AC262536
AC-262536 was designed to selectively bind androgen receptors in muscle and bone tissue
AC-262536 is a Selective Androgen Receptor Modulator (SARM) — studied for its partial agonistactivity at androgen receptors.
In research settings, it has been shown to:
✔ Increase lean body mass.
✔ Improve functional strength.
✔ Support bone health.
📈 MODERATE ANABOLIC EFFECTS:
AC-262536 may provide anabolic benefits with fewer androgenic effects than traditional anabolicagents
⚡️ FUNCTIONAL PERFORMANCE:
Enhances muscle function and endurance in preclinical research.
🛡️ BONE PROTECTION:
Helps maintain bone mass under conditions of hormonal deficiency.
1. Pharmacological characterization of AC‑262,536, a novel selective androgen receptor modulator
https://www.sciencedirect.com/science/article/pii/S0960076007002713
2. Equine metabolism of the selective androgen receptor modulator AC‑262,536 in vitro and in urine, plasma and hair following oral administration
https://www.sciencedirect.com/science/article/pii/S0960076007002713
3. Deciphering the selective androgen receptor modulators paradigm
https://www.expertopinionondrugdiscovery.com/article/10.1517/17460441.2013.741582
4. Simultaneous detection of different chemical classes of selective androgen receptor modulators in urine by liquid chromatography‑mass spectrometry‑based techniques
https://www.sciencedirect.com/science/article/pii/S0960076007002713
Research summary on GW-0742
Microglial Function & Glucose Regulation
GW-0742 is technically not a SARM — it is a PPARδ agonist, closely related to Cardarine(GW-501516).
In research settings, it has been shown to:
✔ Increase fatty acid metabolism.
✔ Improve cardiovascular endurance.
✔ Support healthy lipid profiles.
🥩 FAT UTILIZATION:
Shifts metabolism toward fatty acid oxidation during exercise.
⚡ ENDURANCE PERFORMANCE:
Increases exercise time to exhaustion in research models.
❤️🔥 CARDIOMETABOLIC HEALTH:
Improves markers of cardiovascular and metabolic health.
1. GW0742, a selective PPAR-β/δ agonist, contributes to the resolution of inflammation after gut ischemia/reperfusion injury
https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.13316
2. GW0742 rescued overweight and glucose tolerance, reduced hepatic inflammation, and favored β‑oxidation
https://www.sciencedirect.com/science/article/pii/S0303720718301059
3. GW0742 context‑dependent regulation in endothelial cells—suppressed metabolism in monolayers but enhanced during tubulogenesis
https://www.nature.com/articles/s41598-020-63900-0.pdf
4. PPARδ activation by GW0742 increases cardiac metabolic gene expression and lipid catabolism
https://www.thieme-connect.com/products/ejournals/html/10.1055/s-0033-1348317
Research summary on GSK2881078
Designed to treat muscle weakness and cachexia, particularly in aging and chronic illness contexts.
GSK-2881078 is a Selective Androgen Receptor Modulator (SARM) — investigated for age-relatedmuscle loss and physical function decline.
In research settings, it has been shown to:
✔ Increase lean muscle mass in older adults
✔ Enhance walking speed and physical capacity.
✔ Improve muscle strength.
⚙️ SARCOPENIA MANAGEMENT:
Has been shown to counteract muscle loss in age-related sarcopenia models.
➡️ FUNCTIONAL MOBILITY:
Improves mobility metrics such as walking speed and stair-climbing power.
⚡️ STRENGTH IMPROVEMENT:
Increases in grip and leg strength have been observed in trials.
1. Safety, tolerability, pharmacokinetics, and pharmacological effects of GSK 2881078 in healthy subjects
https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.13316
2. GSK 2881078 produces dose-dependent increases in lean mass in older adults
https://academic.oup.com/jcem/article/103/9/3215/5047294
3. SARM treatment for muscle weakness in COPD: Phase II trial
https://thorax.bmj.com/content/78/3/258
4. Clinical trial registration: 13-week SARM GSK 2881078 in older men and post-menopausal women with COPD
https://clinicaltrials.gov/study/NCT03359473
5. Structural comparison of RAD-140, GLPG 0492, and GSK 2881078 via docking studies
https://www.sciencedirect.com/science/article/pii/S0960076018306885
Explore the best stack options.
